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of Abdominal Aortic Aneurysm’With great interest we read the article, insulin-like growth
factor 1 – A novel biomarker of abdominal aortic aneurysm by Lind-
holt et al.1 Biomarker research for abdominal aortic aneurysm
(AAA) development, progression, and rupture has attracted a lot
of interest.2 Although this ﬁeld holds promise, biomarker studies
are complex and challenging in AAA disease. Lindholt and
colleagues have revealed many interesting biomarkers, and there-
fore the authors are applauded.
Circulating insulin-like growth factor 1 (IGF-1) is produced
by the liver. IGF-1 has different biological functions such as
regulating cell growth, differentiation, migration and cell
survival. IGF-1 binds to IGF-1 receptors, and is modulated by
IGF binding proteins.3 Total circulating IGF-1 concentrations
are not inﬂuenced by diurnal or circadian variation, which is
an advantage for biomarker research.4 In their latest study,
Lindholt et al. showed that serum IGF-1 concentrations are posi-
tively correlated with AAA size, AAA growth rate, and predicted
future need for preventive surgery. IGF-1 is an interesting
biomarker because recombinant IGF-1 therapy decreases prote-
olysis and protein oxidation. These processes are highly
increased in AAA diseased tissues.5 However, several points
needs to be addressed.
AAA progression is slower in diabetics.6 Patients with type 2
diabetes or impaired glucose tolerance are associated with altered
circulating concentrations of IGF-1.4 We wonder if the study
cohort only consists of non-diabetics. If not, it would be interesting
to include diabetes/HbA1c values in addition to glucocorticoids
(upregulated by many factors, for instance, by physical stress
and inﬂammation) in the multivariable analysis to investigate
whether this factor has inﬂuence on the strength of the associa-
tion. Furthermore, the investigators performed a ROC-curve anal-
ysis of serum IGF-1 concentrations and the need for surgery. The
area under the curve (AUC) was 0.63 with a 95% conﬁdence
interval (C.I.) of 0.52–0.73. The authors also showed an AUC of
0.93 (95%, C.I 0.88–0.97) for AAA growth rate and the need for
surgery. It would be interesting to calculate the AUC of serum
IGF-1 and AAA growth rate combined. This reveals whether
measurements of serum IGF-1 holds additional value for predict-
ing the need for surgery besides AAA growth rate as the sole
predictor.
The authors also performed survival analyses and Cox regres-
sions with serum IGF-1 concentrations for cardiovascular events,
death, and the need for later surgery. No predictive valuewas found
for cardiovascular events and death. What deﬁnition did the
authors use for cardiovascular events and how many events
occurred? The statistical power might have hampered theseDOI of original article: 10.1016/j.ejvs.2011.12.020.analyses, especially with heterogeneous endpoints such as death
or cardiovascular events.References
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